Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00854152 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 121
- Enrollment target
NCT00854152 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 121 participants.
The verdict
NCT00854152, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with incurable, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen or for which there is no standard therapy.
Interventions
- DRUG GDC-0980
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2009-03 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00854152
The ClinicalTrials.gov registry entry for NCT00854152 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GDC-0980 is the first listed.
NCT00854152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00854152 about?
NCT00854152 is a clinical study titled "A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma". This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with incurable, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one p...
What is the current status of trial NCT00854152?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 121 participants. The study started on 2009-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00854152?
The interventions under investigation include: GDC-0980 (DRUG).
Who is sponsoring clinical trial NCT00854152?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.